TRT Marketing, Q2 2026: Enforcement, Search Demand, and AI Visibility

Why do testosterone clinics keep drawing regulators when the therapy itself is legal and widely prescribed? In the trailing 12 months, regulators brought 5 tracked enforcement actions against TRT marketing, up +400% from 1 a year earlier, while patients run about 32,835 buyer-intent searches a month. When prospective patients ask AI assistants where to get trt care, the engines named a specific provider in 87% of answers. This is the Q2 2026 edition of Authoritize’s quarterly TRT report, covering the trailing 12 months.

By the numbers

Metric	Value
Tracked enforcement actions (all time)	13
Enforcement actions, last 12 months	5
Enforcement actions, prior 12 months	1
Year-over-year change	+400%
TRT-adjacent actions (other categories)	20
Monthly buyer-intent searches	32,835
Average keyword difficulty (0-100)	26
AI answers naming a specific provider	87%

The Grey Market Problem: Why Most TRT Enforcement Has Nothing to Do With Your Clinic

Testosterone replacement therapy sits at an unusual regulatory crossroads. The clinical core, physician-diagnosed hypogonadism treated with federally approved medications, is well-established medicine. The enforcement story, however, is not really about that core. It is mostly about what has grown around it: SARMs positioned as supplements, compounded testosterone marketed like a catalog product, and “hormone optimization” language that consistently outruns the evidence base. Understanding that split is the first step toward building a practice that neither draws regulatory attention nor gets buried under national telehealth brands in search.

When the Numbers Look Small, Read the Trajectory

The Authoritize Atlas currently holds 13 tracked enforcement actions in the TRT category. That may sound modest. It isn’t, once you look at the velocity. Five of those actions landed in the trailing 12 months, compared to 1 in the prior 12-month period. That is a +400% year-over-year increase, moving from a near-dormant enforcement environment to an active one inside a single calendar year.

Fines remain rare in this space so far. The trajectory, though, is the story. Regulatory agencies do not typically accelerate enforcement and then stop. When volume rises this sharply, the period before fines become routine is exactly when a clinic’s practices become baked in, for better or worse. A single penalty in an adjacent vertical ran to six figures. That tail cost is the right frame for evaluating compliance risk, not a count of how many fines have been issued yet.

The 5 direct TRT actions also do not capture the full picture. A further 20 enforcement actions hit TRT-adjacent marketing, covering SARMs, compounded testosterone, and anabolic products. For a physician-run hormone clinic, those adjacent categories matter because regulators do not always draw the lines that marketers assume they do. A clinic that resells or references “hormone optimization stacks” that include SARMs, or that promotes compounded testosterone with claims that no compounded preparation can legally carry, is operating in grey-market territory even if the clinic itself is fully licensed.

The Violation That Keeps Appearing: Unsubstantiated Efficacy Claims

Across the TRT corpus, one violation category dominates: Unsubstantiated efficacy claims, flagged 33 times. That figure alone tells you where the regulatory exposure concentrates. It is not primarily in labeling errors or procedural omissions. It is in what clinics say a treatment will do for a patient.

The pattern shows up in several forms. Outcome promises that present testosterone therapy as a near-certain solution for energy, body composition, or sexual function. Before-and-after framing that implies overstated results without the clinical caveats that honest patient communication requires. “Hormone optimization” as a phrase is not inherently problematic, but it is frequently paired with claims that specific, measurable improvements are expected, and that is where the FTC’s substantiation standard becomes relevant.

Compounded testosterone marketing has been a recurring flashpoint. Compounding pharmacies operate under a different regulatory framework than manufacturers of federally approved drugs, and enforcement actions in this space have specifically targeted promotions that present compounded formulations as equivalent to or better than approved alternatives without adequate substantiation. When a hormone clinic’s website treats compounded preparations as routine menu items, it is borrowing the grey market’s risk exposure even if the clinic is otherwise well-run.

SARMs deserve a separate word. Selective androgen receptor modulators are not approved for human use. They are not supplements, regardless of how they are labeled or marketed. Clinics that mention them approvingly, link to products, or allow patient-facing content to treat them as part of a testosterone optimization protocol are operating in the highest-risk portion of this space, and the 20 adjacent enforcement actions reflect that.

What the Periphery Looks Like, and How a Clinic Distinguishes Itself

The grey market that surrounds legitimate hormone replacement therapy has a recognizable profile. It tends to lead with transformation language rather than diagnostic language. It presents treatment as a lifestyle upgrade rather than the management of a clinical condition. It uses testimonial-heavy formats that implicitly make the outcome promises that explicit copy cannot. And it blurs the line between supplementation, compounding, and pharmaceutical treatment in ways that are convenient for marketing but indefensible under scrutiny.

A legitimate, physician-run clinic does the opposite on every axis. Patient-facing content starts from the diagnostic process: what low testosterone is, how it is measured, and what the clinical threshold for treatment looks like. It presents testosterone therapy as a medically supervised intervention, not a wellness upgrade. Claims are specific and attributable to primary literature or clinical guidelines, and they are reviewed by the prescribing physician before they go on the website. The marketing reflects the actual informed consent conversation a patient would have in the office.

That is not just a compliance posture. It is also, as the search data shows, an opportunity.

The Search Landscape: Where the Opens Are

Patients run 32,835 TRT searches a month across buyer-intent terms. That is a substantial, actively converting audience. The average cost-per-click across those terms is $8.31, and keyword difficulty averages 26 out of 100. That 26 is a relatively accessible number for a category this commercially active, which signals that organic content can compete, if it is aimed at the right targets.

The caveat is important. Broad national head terms, generic searches for testosterone therapy or low-T treatment, are now owned by national direct-to-consumer telehealth brands. Across 15 AI-generated answers to TRT buyer questions, 13 named a specific provider, representing 87% of answers. The incumbents capturing those AI citations include Defy Medical, Hone Health, Peter MD, Hims, Fountain TRT, Male Excel, Maximus, and TRT Nation. These are companies with the content volume, domain authority, and publishing infrastructure to maintain visibility in both traditional search and AI answer engines. A single clinic cannot displace them on broad terms, and attempting to compete there directly is a poor allocation of marketing resources.

Local and condition-specific intent is a different story. Searches tied to a city, a named practitioner, a specific protocol, or a patient’s particular symptoms and diagnostic questions still represent open ground. A patient who already has a diagnosis and is evaluating local providers is not well-served by a national telehealth platform. A patient searching for a specific protocol or asking about a particular medication class is often looking for clinical depth that a national DTC brand’s content does not provide.

Compliance and Search Visibility Are the Same Work

This is the point that often gets missed in the compliance-versus-marketing framing. Google’s quality rater guidelines treat health content as YMYL, “Your Money or Your Life,” and apply the highest E-E-A-T standard to it: Experience, Expertise, Authoritativeness, and Trustworthiness. The characteristics that make health content score well on those dimensions, named authors with verifiable credentials, claims tied to cited sources, content that reflects real clinical process, are exactly the characteristics that make marketing defensible under FDA and FTC scrutiny.

A page that describes the diagnostic workup for low testosterone, cites the relevant clinical guidelines, carries the name of the reviewing physician, and accurately represents what treatment can and cannot accomplish is simultaneously good medical marketing and helpful, people-first content by Google’s own definition. A page that leads with transformation promises and buries the clinical context to maximize conversion is neither.

The unsubstantiated efficacy claim problem, flagged 33 times in the Atlas, does not appear in physician-reviewed content built around honest clinical communication. It appears in content written to a marketing brief that was never reviewed for accuracy against what the evidence actually supports.

The compliance project and the content marketing project, when done correctly, produce the same asset. That alignment is not incidental. It reflects the fact that regulators and search engines are both trying to answer the same question: can a patient trust what this source says?

---

Methodology

Enforcement figures for TRT are drawn from the Authoritize Atlas, a curated, operator-reviewed library of FDA warning letters and FTC enforcement actions in healthcare and wellness marketing. The TRT corpus holds 13 published actions; trend comparisons use trailing-12-month windows anchored to 2026-06-30. The Atlas is keyword-gated, so it represents a meaningful sample of enforcement activity in this vertical, not a complete census of every regulatory action taken.

Marketing figures for TRT are measured by Authoritize. Search demand, CPC, and keyword difficulty come from DataForSEO across 13 buyer-intent terms at United States national scope; monthly volume uses Keyword Planner where available and a clickstream estimate for terms the Planner buckets. The AI-search analysis runs 5 buyer questions through ChatGPT, Perplexity, and Google Gemini with web search enabled, then checks each answer against a curated list of known providers in the vertical. Because that list is curated rather than exhaustive, the share of answers naming a tracked provider is a floor, not a ceiling. Demand figures reflect search interest, not patient counts.

For clinics, the practical implication of both data lanes is the same. Enforcement is accelerating, and it concentrates on claims that outrun the evidence. Search visibility, especially the AI-answer layer now shaping how patients find providers, rewards exactly the kind of accurate, specific, physician-reviewed content that enforcement agencies cannot fault. Build content around the diagnostic process, name the clinicians responsible for it, cite your sources, and keep every claim to what the evidence supports. That is how a clinic earns citations in AI answers and keeps its marketing defensible, without outsourcing either responsibility.

Frequently asked questions

How much is TRT marketing enforcement growing in 2026? Regulators brought 5 tracked FDA and FTC enforcement actions against TRT marketing in the trailing 12 months, up +400% from 1 a year earlier, drawn from the Authoritize Atlas.

Do AI assistants recommend specific TRT providers? In a test of 15 buyer-intent questions across ChatGPT, Perplexity, and Google Gemini, the assistants named a specific provider in 87% of answers, most often national brands such as Defy Medical, Hone Health, Peter MD.

How much search demand is there for TRT? Patients run about 32,835 buyer-intent TRT searches a month at United States national scope, at an average keyword difficulty of 26 out of 100.

What marketing violation is most common in TRT? Unsubstantiated efficacy claims, flagged 33 times across TRT actions in the Atlas, is the most common.

Is compliant content better for SEO and AI visibility? Yes. Google classifies health information as Your Money or Your Life (YMYL) and holds it to the highest standard of Experience, Expertise, Authoritativeness, and Trust (E-E-A-T). The accuracy and trust signals that earn search and AI visibility are the same ones that make TRT content defensible to the FDA and FTC.

Where can a local TRT clinic still compete? In local and specific intent: searches tied to a city, a named practitioner, or a specific protocol, where national brands are structurally weak and AI answers often name no provider at all.

Sources and further reading

• The enforcement figures come from the Authoritize Atlas, the searchable library of the FDA and FTC actions behind every number here.
• The cross-vertical picture is in the flagship State of Healthcare Marketing and Compliance; other per-vertical editions: GLP-1 and weight loss, medical spa and aesthetics, peptide therapy.
• Screen your own pages, ads, and emails against FDA and FTC patterns with the free Claim Checker.
• Google, Search Quality Rater Guidelines (YMYL and E-E-A-T); Google Search Central, Creating Helpful, Reliable, People-First Content.
• Primary records: U.S. FDA, Warning Letters; U.S. FTC, Cases and Proceedings.